DK2945642T3 - Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme - Google Patents

Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme Download PDF

Info

Publication number
DK2945642T3
DK2945642T3 DK14700872.6T DK14700872T DK2945642T3 DK 2945642 T3 DK2945642 T3 DK 2945642T3 DK 14700872 T DK14700872 T DK 14700872T DK 2945642 T3 DK2945642 T3 DK 2945642T3
Authority
DK
Denmark
Prior art keywords
protein
disease
prevention
factor
treatment
Prior art date
Application number
DK14700872.6T
Other languages
English (en)
Inventor
Kai Christoph Wollert
Mortimer Korf-Klingebiel
Original Assignee
Medizinische Hochschule Hannover
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Hochschule Hannover filed Critical Medizinische Hochschule Hannover
Application granted granted Critical
Publication of DK2945642T3 publication Critical patent/DK2945642T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
DK14700872.6T 2013-01-17 2014-01-16 Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme DK2945642T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13151593 2013-01-17
PCT/EP2014/050788 WO2014111458A2 (en) 2013-01-17 2014-01-16 Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases

Publications (1)

Publication Number Publication Date
DK2945642T3 true DK2945642T3 (da) 2024-05-27

Family

ID=47559322

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14700872.6T DK2945642T3 (da) 2013-01-17 2014-01-16 Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme

Country Status (11)

Country Link
US (1) US10369198B2 (da)
EP (2) EP3747457A3 (da)
JP (3) JP6809789B2 (da)
CN (6) CN104968361B (da)
CA (1) CA2898128A1 (da)
DK (1) DK2945642T3 (da)
FI (1) FI2945642T3 (da)
HK (1) HK1215540A1 (da)
LT (1) LT2945642T (da)
PT (1) PT2945642T (da)
WO (1) WO2014111458A2 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2898128A1 (en) * 2013-01-17 2014-07-24 Medizinische Hochschule Hannover Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
CN105934249A (zh) 2013-11-21 2016-09-07 布里格姆及妇女医院股份有限公司 用于治疗肺高压的组合物和方法
CN114470207B (zh) * 2014-08-01 2023-09-19 布里格姆及妇女医院股份有限公司 与肺动脉高压的治疗有关的组合物和方法
US10435757B1 (en) 2016-06-15 2019-10-08 University Of South Florida Methods of measuring C19MC miRNA in a post-natal tissue and uses thereof
CN108802372B (zh) * 2018-06-19 2021-05-11 上海伦泽生物科技有限公司 检测人血清中内质网膜蛋白复合体亚单位10的试剂盒
WO2021148411A1 (en) 2020-01-21 2021-07-29 Boehringer Ingelheim International Gmbh Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure
CN114149500B (zh) * 2020-09-07 2023-12-01 复旦大学附属华山医院 抗人emc10的单克隆抗体在制备治疗和/或预防脂肪肝的产品中的应用
CN114149498B (zh) * 2020-09-07 2023-12-05 复旦大学附属华山医院 抗人emc10的单克隆抗体在防治2型糖尿病中的应用
CN114149499B (zh) * 2020-09-07 2023-12-05 复旦大学附属华山医院 抗人emc10的单克隆抗体及其在治疗和/或预防肥胖症中的应用
IL303891A (en) 2020-12-23 2023-08-01 Boehringer Ingelheim Int Viral capsid proteins with specificity for cardiac tissue cells
WO2023233034A1 (en) 2022-06-03 2023-12-07 Boehringer Ingelheim International Gmbh Recombinant expression of myeloid-derived growth factor
WO2024052563A1 (en) 2022-09-08 2024-03-14 Boehringer Ingelheim International Gmbh Myeloid-derived growth factor for use in treating cardiogenic shock

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
CA2257137A1 (en) 1996-06-11 1997-12-18 Merck & Co., Inc. Synthetic hepatitis c genes
JP2001506484A (ja) * 1996-09-13 2001-05-22 財団法人相模中央化学研究所 分泌シグナル配列を有するヒト蛋白質およびそれをコードするdna
CA2265923A1 (en) * 1996-09-13 1998-03-19 Sagami Chemical Research Center Human proteins having secretory signal sequences and dnas encoding these proteins
PL334902A1 (en) * 1997-01-29 2000-03-27 Cornell Res Foundation Inc Repeatable local delivery of adenoviral vector in order to induce angiogenesis
CA2374180C (en) 1999-05-26 2012-09-11 Marita Hiipakka Methods and materials for generating sh3 domains with tailored binding properties
AU5441200A (en) * 1999-06-02 2000-12-18 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
AU6590500A (en) * 1999-08-16 2001-03-13 Universita' Degli Studi Di Siena Vegf-d and angiogenic use thereof
JP2004516013A (ja) * 2000-07-20 2004-06-03 ジェネンテック・インコーポレーテッド 血管形成に関連する障害を診断及び治療するための組成物と方法
WO2002081681A1 (fr) * 2001-03-30 2002-10-17 Chugai Seiyaku Kabushiki Kaisha Nouvelle utilisation de la cytokine sf20
DE10119804A1 (de) * 2001-04-23 2002-10-24 Brahms Ag Entzündungsspezifische Peptide und deren Verwendungen
US7452968B2 (en) * 2003-01-02 2008-11-18 University Of Southern California Secreted protein factor and cell membrane-bound splice variant
WO2004069173A2 (en) * 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
US8486438B2 (en) 2004-01-29 2013-07-16 Brown University Methods for progenitor cell recruitment and isolation
CN101160055A (zh) * 2005-02-16 2008-04-09 莱蒂恩公司 慢病毒载体及其用途
US20080004232A1 (en) * 2006-05-09 2008-01-03 John Wilkins Characterization of c19orf10, a Novel Synovial Protein
EP1892248A1 (en) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
EP2130547A1 (en) * 2008-06-06 2009-12-09 Giuliani International Limited IL-25 for use in the treatment of inflammatory diseases
MX2012002605A (es) * 2009-08-29 2012-04-02 Abbott Lab Proteinas terapeutico de union a dll4.
WO2011094446A1 (en) * 2010-01-27 2011-08-04 Neumedicines, Inc A method for treating brain cancer using a novel tumor suppressor gene and secreted factor
KR20120095063A (ko) * 2011-02-18 2012-08-28 가톨릭대학교 산학협력단 IL-27로 유도된 p53을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
CA2898128A1 (en) * 2013-01-17 2014-07-24 Medizinische Hochschule Hannover Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases

Also Published As

Publication number Publication date
EP2945642A2 (en) 2015-11-25
WO2014111458A3 (en) 2014-09-12
HK1215540A1 (zh) 2016-09-02
FI2945642T3 (fi) 2024-05-10
US20150352186A1 (en) 2015-12-10
CN104968361B (zh) 2019-12-17
CN110903378A (zh) 2020-03-24
PT2945642T (pt) 2024-05-27
EP2945642B1 (en) 2024-02-21
CN110922468A (zh) 2020-03-27
US10369198B2 (en) 2019-08-06
CN104968361A (zh) 2015-10-07
JP2016506911A (ja) 2016-03-07
LT2945642T (lt) 2024-06-25
CN111100197A (zh) 2020-05-05
CN110922467A (zh) 2020-03-27
EP3747457A3 (en) 2021-03-03
JP6809789B2 (ja) 2021-01-06
JP2020203894A (ja) 2020-12-24
WO2014111458A2 (en) 2014-07-24
CA2898128A1 (en) 2014-07-24
JP2023025005A (ja) 2023-02-21
EP3747457A2 (en) 2020-12-09
CN110894226A (zh) 2020-03-20

Similar Documents

Publication Publication Date Title
LTC3057969I2 (lt) Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit
DK2945642T3 (da) Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme
DK3334422T3 (da) Anvendelse af cannabidiolsyre i behandling af epilepsi
DK3206715T3 (da) Anvendelse af cannabidiol i behandling af tuberøs sklerosekompleks
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
DK3119397T3 (da) Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
DK3010506T3 (da) Pridopidin i behandling af huntingtons sygdom
DK3811943T3 (da) Forbindelse til anvendelse til behandling af øjenlidelser
DK2935303T3 (da) 4`-fluornukleosider, 4`-fluornukleotider og analoger dertil til behandling af HCV
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3185957T3 (da) Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
DK3302519T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom
DK3226854T3 (da) Aminosyrebaseret sammensætning til genoprettelse af fibroelastin i hudens bindevæv
DK2984184T3 (da) Anvendelse af dnq eller dnq-87 i kombination med en parp1-inhibitor til behandlingen af cancer
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3044229T3 (da) Peptider til anvendelse i behandlingen af oral mucositis
DK3153511T3 (da) 2-acylaminothiazolderivat til anvendelse i forebyggelsen eller behandlingen af blære- og urinvejssygdomme
CL2015000537A1 (es) Siarn y su uso en los métodos y composiciones para el tratamiento y/o prevención de enfermedades de los ojos.
DK3041831T3 (da) Alfa-te-saltformer: sammensætninger og anvendelser til behandling af sygdom
FR3002454B1 (fr) Composition immunogene sous forme d'emulsion
DK3442558T3 (da) Bmp-7-afledte peptider til anvendelse i behandlingen af osteoartritis
DK3423060T3 (da) Imatinib til anvendelse til behandling af slagtilfælde
FR3004424B1 (fr) Marchepied amovible d'aeronef, et aeronef
DK3413870T3 (da) Igmesin til anvendelse ved behandlingen af alzheimers sygdom